Pfizer/BioNTech reported that 80% efficacy of its vaccine was demonstrated in 3 doses for toddlers and children below 5 years. The study included 1678 children during the pandemic period when Omicron was predominant. Based on the study data Pfizer plans to submit an application for EUA to the US FDA. 

Earlier Pfizer asked the US FDA to authorize its vaccine for younger children but delayed its application after the trial data for 2 vaccination doses did not produce a significant immune response. Although the safety of the vaccine was similar to the placebo.

The US FDA advisory board meeting is scheduled on June 15th to evaluate and authorize their recommendations for the mRNA vaccines in children under 6 years old. The doses recommended for children from 6 months to 5 years is 3 micrograms. i.e., 1/10th of the vaccination dosage administered to an adult.